404 related articles for article (PubMed ID: 21466775)
1. [Level of evidence for therapeutic drug monitoring of vancomycin].
Jelassi ML; Benlmouden A; Lefeuvre S; Mainardi JL; Billaud EM;
Therapie; 2011; 66(1):29-37. PubMed ID: 21466775
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Jelassi ML; Benlmouden A; Lefeuvre S; Mainardi JL; Billaud EM;
Therapie; 2011; 66(1):29-37. PubMed ID: 27393462
[TBL] [Abstract][Full Text] [Related]
3. [Level of evidence for therapeutic drug monitoring of aminoglycosides].
Venisse N; Boulamery A;
Therapie; 2011; 66(1):39-44. PubMed ID: 21466776
[TBL] [Abstract][Full Text] [Related]
4. [Level of evidence for therapeutic drug monitoring of teicoplatin].
Boulamery A; Venisse N; Le Guellec C;
Therapie; 2011; 66(1):45-50. PubMed ID: 21466777
[TBL] [Abstract][Full Text] [Related]
5. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.
Ampe E; Delaere B; Hecq JD; Tulkens PM; Glupczynski Y
Int J Antimicrob Agents; 2013 May; 41(5):439-46. PubMed ID: 23523733
[TBL] [Abstract][Full Text] [Related]
6. A higher dose of vancomycin in continuous infusion is needed in critically ill patients.
Jeurissen A; Sluyts I; Rutsaert R
Int J Antimicrob Agents; 2011 Jan; 37(1):75-7. PubMed ID: 21074374
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.
Hochart C; Berthon C; Corm S; Gay J; Cliquennois M; Tricot S; Alfandari S
Med Mal Infect; 2011 Dec; 41(12):652-6. PubMed ID: 22056376
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
Kitzis MD; Goldstein FW
Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
[TBL] [Abstract][Full Text] [Related]
10. Dosage adjustment of antiinfective therapy in patients with renal impairment.
Eckhardt A; Borner K; Keller F; Zellner D
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):99-102. PubMed ID: 9088997
[TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
Thomson AH; Staatz CE; Tobin CM; Gall M; Lovering AM
J Antimicrob Chemother; 2009 May; 63(5):1050-7. PubMed ID: 19299472
[TBL] [Abstract][Full Text] [Related]
12. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
[TBL] [Abstract][Full Text] [Related]
13. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.
Kullar R; Leonard SN; Davis SL; Delgado G; Pogue JM; Wahby KA; Falcione B; Rybak MJ
Pharmacotherapy; 2011 May; 31(5):441-8. PubMed ID: 21923425
[TBL] [Abstract][Full Text] [Related]
14. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
Fung L
Ann Pharmacother; 2012 Oct; 46(10):e26. PubMed ID: 23032658
[TBL] [Abstract][Full Text] [Related]
15. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.
Hutschala D; Kinstner C; Skhirdladze K; Thalhammer F; Müller M; Tschernko E
Anesthesiology; 2009 Aug; 111(2):356-65. PubMed ID: 19602966
[TBL] [Abstract][Full Text] [Related]
16. Review of continuous-infusion vancomycin.
DiMondi VP; Rafferty K
Ann Pharmacother; 2013 Feb; 47(2):219-27. PubMed ID: 23386074
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.
Zhao W; Lopez E; Biran V; Durrmeyer X; Fakhoury M; Jacqz-Aigrain E
Arch Dis Child; 2013 Jun; 98(6):449-53. PubMed ID: 23254142
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.
Fernández de Gatta MD; Calvo MV; Hernández JM; Caballero D; San Miguel JF; Domínguez-Gil A
Clin Pharmacol Ther; 1996 Sep; 60(3):332-40. PubMed ID: 8841156
[TBL] [Abstract][Full Text] [Related]
19. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity.
Darko W; Medicis JJ; Smith A; Guharoy R; Lehmann DE
Pharmacotherapy; 2003 May; 23(5):643-50. PubMed ID: 12741439
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.
Ingram PR; Lye DC; Tambyah PA; Goh WP; Tam VH; Fisher DA
J Antimicrob Chemother; 2008 Jul; 62(1):168-71. PubMed ID: 18334494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
